Pharmacotherapy of allergic rhinitis: A pharmaco-economic approach

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 1, 2009, Pages 85-95

  Simoens, S ^a   Laekeman, G ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Allergic rhinitis; Costs; Economic evaluation; Pharmaco economics; Pharmacotherapy

Indexed keywords

BUDESONIDE; CETIRIZINE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE; LEVOCABASTINE; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; PLACEBO; SALBUTAMOL; TERFENADINE;

ABSENTEEISM; ALLERGIC RHINITIS; AMBULATORY CARE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG DOSAGE FORM COMPARISON; HAY FEVER; HEALTH CARE COST; HUMAN; MEDICAL FEE; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SAMPLE SIZE; SYSTEMATIC REVIEW;

CETIRIZINE; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 58149127816     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01909.x     Document Type: Review

References (52)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 (Suppl.5 147 334.
2. Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs. nonallergic. Am Fam Physician 2006 73 : 1583 1590.
3. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991 46 : 895 901.
4. International Rhinitis Management Working Group. International consensus report on diagnosis and management of rhinitis. Allergy 1994 49 (Suppl. 19 1 34.
5. Dykewicz MS, Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol 1998 81 : 463 468.
6. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008 63 (Suppl. 86 8 160.
7. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000 55 : 116 134.
8. Al Sayyad JJ, Fedorowicz Z, Alhashimi D, Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev 2007 (Issue 1).
9. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc 2007 28 : 3 9.
10. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007 62 (Suppl. 84 1 41.
11. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994 94 : 182 188.
12. Nascimento Silva M, Naspitz C, Sole D. Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Allergol Immunopathol (Madr) 2001 29 : 111 118.
13. Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L et al. The work impact of asthma and rhinitis. Findings from a population based survey. J Clin Epidemiol 2001 54 : 610 618.
14. Szeinbach SL, Seoane-Vazquez EC, Beyer A, Williams PB. The impact of allergic rhinitis on work productivity. Prim Care Respir J 2007 16 : 98 105.
15. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999 104 : 364 369.
16. Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin 2004 20 : 1937 1952.
17. Santos CB, Pratt EL, Hanks C, McCann J, Craig TJ. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 2006 97 : 579 586.
18. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, disturbed cognitive functions and psychological well-being. Clin Exp Allergy 2002 32 : 1310 1315.
19. Bavbek S, Kumbasar H, Tugcu H, Misirligil Z. Psychological status of patients with seasonal and perennial allergic rhinitis. J Investig Allergol Clin Immunol 2002 12 : 204 210.
20. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003 (Issue 2).
21. Penagos M, Compalati E, Tarantini F, Baena-Cagnani R, Huerta J, Passalacqua G et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006 97 : 141 148.
22. Long A, McFadden C, DeVine D, Chew P, Kupelnick B, Lau J. Management of allergic and nonallergic rhinitis. Rockville, MD : Agency for Healthcare Research and Quality, 2002.
23. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. Br Med J 1998 317 : 1624 1629.
24. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes, 3rd Rev. edn. Oxford : Oxford University Press, 2005.
25. Reed SD, Lee TA, McCrory DC. The economic burden of allergic rhinitis. A critical evaluation of the literature. Pharmacoeconomics 2004 22 : 345 361.
26. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001 107 : 3 8.
27. Schoenwetter WF, Dupclay L Jr., Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin 2004 20 : 305 317.
28. Celik G, Mungan D, Abadoǧlu O, Pinar NM, Misirligil Z. Direct cost assessments in subjects with seasonal allergic rhinitis living in Ankara, Turkey. Allergy Asthma Proc 2004 25 : 107 113.
29. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-year retrospective study. Eur Respir J 2003 21 : 116 122.
30. Dessi P, Allaert FA, Urbinelli R, Verriere JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allergy Immunol 1998 30 : 277 283.
31. Crown WH, Olufade A, Smith MW, Nathan R. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health 2003 6 : 448 456.
32. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C et al. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005 60 : 788 794.
33. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy Asthma Immunol 1994 73 : 35 39.
34. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997 99 : 22 27.
35. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003 111 : 296 300.
36. Storms W, Meltzer EO, Nathan RA, Selner JC. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997 99 : 820 824.
37. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006 22 : 1203 1210.
38. Mackowiak JI. The health and economic impact of rhinitis. Am J Managed Care 1997 3 : 8 18.
39. Ciprandi G, Tosca M, Passalacqua G, Canonica GW. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001 87 : 222 226.
40. Sullivan PW, Follin SL, Nichol MB. Cost-benefit analysis of first-generation antihistamines in the treatment of allergic rhinitis. Pharmacoeconomics 2004 22 : 929 942.
41. Kozma CM, Schulz RM, Sclar DA, Kral KM, Mackowiak JI. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996 18 : 334 346.
42. Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005 95 : 272 282.
43. Keith PK, Haddon J, Birch S, the Rhinocort Study Group. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2000 84 : 55 62.
44. Ståhl E, van Rompay W, Wang ECY, Thomson DMP. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000 84 : 397 402.
45. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy, Asthma Immunol 2004 114 : 838 844.
46. Sullivan PW, Follin SL, Nichol MB. Transitioning the second-generation antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care 2003 41 : 1382 1395.
47. Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007 136 (Suppl. 6 107 124.
48. Brunton SA, Fromer LM. Treatment options for the management of perennial allergic rhinitis, with a focus on intranasal corticosteroids. South Med J 2007 100 : 701 708.
49. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004 291 : 2359 2366.
50. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991 21 : 77 83.
51. The EuroQol Group. EuroQoL - a new facility for the measurement of health-related quality of life. Health Pol 1990 16 : 199 208.
52. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 30 : 473 483.